StreetInsider.com News Articles

Myriad Genetics releases MRD cancer detection data at ESMO 2026

Thu, 22 Oct 2026 09:05:42 -0400

Myriad Genetics, Inc. (NASDAQ: MYGN) released new data from its ongoing MONSTAR-SCREEN-3 study showing results from its whole-genome sequencing-based Precise MRD platform for detecting molecular residual disease in patients with resectable colorectal and pancreatic cancers, according to a company press release.

The findings are being presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 25, 2026.

In patients with resectable colorectal cancer, circulating tumor DNA (ctDNA) detected one month after surgery was associated with disease progression. ctDNA was detected prior to clinical recurrence in all observed recurrence events, with a median lead time of four months. More than

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Thu, 22 Oct 2026 09:05:00 -0400

Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgery

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers.

The findings, which will be presented as part of the European Society

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Thu, 22 Oct 2026 09:05:00 -0400

Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgery

The findings, which will be presented as part of the European Society

TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN)

Tue, 20 Oct 2026 12:11:18 -0400

TD Cowen analyst Kyle Boucher reiterated a Hold rating and $4.50 price target on Myriad Genetics (NASDAQ: MYGN)

The analyst comments "This morning (link) MYGN announced an agreement to sell the Prenatal Health business to Labcorp for $210M in cash (~1.3x '27E sales). The divestiture makes sense - it simplifies the story & product portfolio, should help growth and profitability, and allow more focus on the Cancer Care Continuum. Shares are still <1x '27E sales with stock up >30%, but gaining visibility on growth profile is key."

For an analyst ratings summary and ratings history on Myriad Genetics click here. For

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Investing.com -- Myriad Genetics Inc (NASDAQ:MYGN) shares jumped 36% Tuesday following the company's announcement that it will sell its Prenatal Health testing business to Labcorp Holdings Inc (NYSE:LH) for $210 million in cash, plus inventory value at closing.

The transaction includes Myriad's Prequel, Foresight, SneakPeek, and FirstGene tests. The prenatal testing portfolio generated approximately $160 million in revenue over the last twelve months and served over 600,000 patients.

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Piper Sandler Upgrades Myriad Genetics (MYGN) to Neutral

Tue, 20 Oct 2026 10:57:52 -0400

Piper Sandler analyst Dave Westenberg upgraded Myriad Genetics (NASDAQ: MYGN) from Underweight to Neutral with a price target of $5.00.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $4.21 yesterday.

Myriad Genetics to sell prenatal testing unit to Labcorp for $210M

Tue, 20 Oct 2026 09:03:41 -0400

Myriad Genetics (NASDAQ: MYGN) has agreed to sell its Prenatal Health testing business to Labcorp (NYSE: LH) for $210 million in cash, plus the value of inventory at closing, according to a press release issued Oct. 20, 2026.

The business being sold includes the Prequel, Foresight, SneakPeek, and FirstGene tests, which have been used by more than 600,000 patients and thousands of providers over the past twelve months.

Labcorp expects the acquisition to add approximately $160 million in revenue in its first year, be slightly accretive to adjusted earnings in year one, and reach average diagnostics segment margins by the end of

Myriad Genetics to sell prenatal testing unit to Labcorp for $210M

Tue, 20 Oct 2026 09:03:41 -0400

The business being sold includes the Prequel, Foresight, SneakPeek, and FirstGene tests, which have been used by more than 600,000 patients and thousands of providers over the past twelve months.

Form 8-K MYRIAD GENETICS INC For: Oct 19

Tue, 20 Oct 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20261020/27207295.html

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel^®, Foresight^®, SneakPeek^®, and FirstGene^® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

Thu, 15 Oct 2026 16:05:00 -0400

SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4, 2026. The company’s quarterly earnings will be released the same day after market close. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2026.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

Thu, 15 Oct 2026 16:05:00 -0400

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at

Myriad Genetics (MYGN) PT Raised to $4.50 at TD Cowen

Tue, 13 Oct 2026 09:32:13 -0400

TD Cowen analyst Kyle Boucher raised the price target on Myriad Genetics (NASDAQ: MYGN) to $4.50 (from $4.00) while maintaining a rating.

Form 8-K MYRIAD GENETICS INC For: Oct 06

Fri, 09 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261009/27171715.html

Myriad Genetics and SOPHiA Genetics team up on prostate cancer test

Thu, 08 Oct 2026 09:01:21 -0400

Myriad Genetics (NASDAQ: MYGN) and SOPHiA Genetics (NASDAQ: SOPH) announced a collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, working alongside AstraZeneca (NYSE: AZN) to support precision oncology approaches.

PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. Myriad developed the technology using its MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, which will produce the PrGIS score as the company pursues prostate cancer as a new indication.

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines

Myriad Genetics and SOPHiA Genetics team up on prostate cancer test

Thu, 08 Oct 2026 09:01:21 -0400

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines

Myriad Genetics and SOPHiA Genetics team up on prostate cancer test

Thu, 08 Oct 2026 09:01:21 -0400

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Thu, 08 Oct 2026 09:00:00 -0400

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Thu, 08 Oct 2026 09:00:00 -0400